Proof of Concept, Twice Daily Applications of LEO 124249 Ointment in the Treatment of Chronic Hand Eczema
Primary Purpose
Hand Eczema
Status
Completed
Phase
Phase 2
Locations
Germany
Study Type
Interventional
Intervention
LEO 124249 ointment
LEO 124249 ointment vehicle
Sponsored by
About this trial
This is an interventional treatment trial for Hand Eczema
Eligibility Criteria
Inclusion Criteria:
- Clinical diagnosis of chronic hand eczema with or without atopic etiology/background with a history of not adequately controlled disease activity with cutaneously applied steroid
- Physician's Global Assessment of disease severity graded as at least mild at Visit 1
- In overall good health including well controlled diseases
Exclusion Criteria:
- Systemic treatment with immunosuppressive drugs (e.g. methotrexate, cyclosporine, azathioprine), retinoids (e.g. alitretinoin) or corticosteroids within 6 weeks prior to randomization (inhaled or intra-nasal steroids corresponding to up to 1 mg prednisone for asthma or rhinitis may be used).
- PUVA (Psoralen Ultraviolet A) or UVB (Ultraviolet B) therapy on the hands within 4 weeks prior to randomization
- Cutaneously applied treatment with immunomodulators (pimecrolimus, tacrolimus) or corticosteroids on the hands within 2 weeks prior to randomization.
- Use of systemic antibiotics or cutaneously applied antibiotics on the hands within 2 weeks prior to randomization
- Concurrent skin diseases on the hands
- Current diagnosis of exfoliative dermatitis
- Significant clinical infection (impetiginized hand eczema) on the hands which requires antibiotic treatment
- A marked abnormal ECG at baseline
- Known hepatic dysfunction or hepatic dysfunction tested at Screening
- Current participation in any other interventional clinical trial
Sites / Locations
- Allergie-Centrum-Charité Klinik für Dermatologie, Venerologie und Allergologie
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
LEO 124249 ointment
LEO 124249 ointment vehicle
Arm Description
Twice daily cutaneous application for 8 weeks
Twice daily cutaneous application for 8 weeks
Outcomes
Primary Outcome Measures
Subjects with treatment success according to Physician's Global Assessment (PGA) at visit 6 (End of Treatment)
Treatment success according to the PGA is defined as: Subjects having mild disease at baseline must achieve clear. Subjects having moderate or severe disease at baseline must achieve clear or almost clear
Secondary Outcome Measures
Hand Eczema Severity Index (HECSI) at visit 6
Subjects with treatment success according to the Patient's Global Assessment of disease severity (PaGA) at visit 6 (End of Treatment)
Treatment success according to the PaGA is defined as: Subjects having very mild or mild disease at baseline must achieve clear. Subjects having moderate or severe disease at baseline must achieve clear or very mild
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02664805
Brief Title
Proof of Concept, Twice Daily Applications of LEO 124249 Ointment in the Treatment of Chronic Hand Eczema
Official Title
A Phase 2a, Proof of Concept Trial, Testing Twice Daily Applications of LEO 124249 Ointment in the Treatment of Chronic Hand Eczema
Study Type
Interventional
2. Study Status
Record Verification Date
March 2018
Overall Recruitment Status
Completed
Study Start Date
February 2016 (undefined)
Primary Completion Date
July 2016 (Actual)
Study Completion Date
October 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
LEO Pharma
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
To compare the efficacy of twice daily applications of LEO 124249 ointment with LEO 124249 ointment vehicle for up to 8 weeks in the treatment of subjects with chronic hand eczema.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hand Eczema
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
91 (Actual)
8. Arms, Groups, and Interventions
Arm Title
LEO 124249 ointment
Arm Type
Active Comparator
Arm Description
Twice daily cutaneous application for 8 weeks
Arm Title
LEO 124249 ointment vehicle
Arm Type
Placebo Comparator
Arm Description
Twice daily cutaneous application for 8 weeks
Intervention Type
Drug
Intervention Name(s)
LEO 124249 ointment
Intervention Description
Ointment
Intervention Type
Drug
Intervention Name(s)
LEO 124249 ointment vehicle
Intervention Description
Ointment vehicle
Primary Outcome Measure Information:
Title
Subjects with treatment success according to Physician's Global Assessment (PGA) at visit 6 (End of Treatment)
Description
Treatment success according to the PGA is defined as: Subjects having mild disease at baseline must achieve clear. Subjects having moderate or severe disease at baseline must achieve clear or almost clear
Time Frame
56 days
Secondary Outcome Measure Information:
Title
Hand Eczema Severity Index (HECSI) at visit 6
Time Frame
56 days
Title
Subjects with treatment success according to the Patient's Global Assessment of disease severity (PaGA) at visit 6 (End of Treatment)
Description
Treatment success according to the PaGA is defined as: Subjects having very mild or mild disease at baseline must achieve clear. Subjects having moderate or severe disease at baseline must achieve clear or very mild
Time Frame
56 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Clinical diagnosis of chronic hand eczema with or without atopic etiology/background with a history of not adequately controlled disease activity with cutaneously applied steroid
Physician's Global Assessment of disease severity graded as at least mild at Visit 1
In overall good health including well controlled diseases
Exclusion Criteria:
Systemic treatment with immunosuppressive drugs (e.g. methotrexate, cyclosporine, azathioprine), retinoids (e.g. alitretinoin) or corticosteroids within 6 weeks prior to randomization (inhaled or intra-nasal steroids corresponding to up to 1 mg prednisone for asthma or rhinitis may be used).
PUVA (Psoralen Ultraviolet A) or UVB (Ultraviolet B) therapy on the hands within 4 weeks prior to randomization
Cutaneously applied treatment with immunomodulators (pimecrolimus, tacrolimus) or corticosteroids on the hands within 2 weeks prior to randomization.
Use of systemic antibiotics or cutaneously applied antibiotics on the hands within 2 weeks prior to randomization
Concurrent skin diseases on the hands
Current diagnosis of exfoliative dermatitis
Significant clinical infection (impetiginized hand eczema) on the hands which requires antibiotic treatment
A marked abnormal ECG at baseline
Known hepatic dysfunction or hepatic dysfunction tested at Screening
Current participation in any other interventional clinical trial
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Margitta Worm, Prof Dr
Organizational Affiliation
Allergie-Centrum-Charité Klinik für Dermatologie, Venerologie und Allergologie
Official's Role
Principal Investigator
Facility Information:
Facility Name
Allergie-Centrum-Charité Klinik für Dermatologie, Venerologie und Allergologie
City
Berlin
ZIP/Postal Code
10117
Country
Germany
12. IPD Sharing Statement
Learn more about this trial
Proof of Concept, Twice Daily Applications of LEO 124249 Ointment in the Treatment of Chronic Hand Eczema
We'll reach out to this number within 24 hrs